|
November 2019
Billing chart: Blues highlight medical, benefit policy changes
You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.
This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.
You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.
We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.
For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:
- Log in to web-DENIS.
- Click on BCBSM Provider Publications & Resources.
- Click on Benefit Policy for a Code.
- Click on Topic.
- Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
- Enter the procedure code.
- Click on Finish.
- Click on Search.
| Code* |
BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
|
| UPDATES TO PAYABLE PROCEDURES |
E0650, E0651, E0660, E0666, E0667, E0669 |
Basic benefit and medical policy
Pneumatic compression pumps for venous ulcers
Pneumatic compression pumps and appliances (nonprogrammable) for lower extremities are established. It may be considered a useful therapeutic option when indicated. Policy updates are effective Nov. 1, 2019.
Inclusions:
Pneumatic compression devices are established for the treatment of chronic venous insufficiency, or CVI, of the lower extremities only if all of the following are present:
- Edema in the affected lower extremity
- One or more venous stasis ulcer
- The ulcers have failed to heal after a six-month trial of conservative therapy directed by the treating physician.
Six-month trial for CVI
A six-month trial of conservative therapy demonstrating failed response to treatment is required. The six-month trial of conservative therapy must include all of the following:
- Compliant use of an appropriate compression bandage system or compression garment to provide adequate graduated compression
- Adequate compression is defined as:
1) Sufficient pressure at the lowest pressure point to cause fluid movement, and
2) Sufficient pressure across the gradient (from highest to lowest pressure point) to move fluid from distal to proximal. The compression used must not create a tourniquet effect at any point.
- The garment may be prefabricated or custom fabricated but must provide adequate graduated compression starting with a minimum of 30 mmHg distally.
- Medications as appropriate (e.g., diuretics or other treatment of congestive failure, etc.)
- Regular exercise
- Elevation of the limb
- Appropriate wound care for the ulcer (including sharp debridement where appropriate)
Exclusions:
- Pneumatic compression devices used to treat ulcers in locations other than the lower extremity or ulcers and wounds from other causes.
- At the end of the six-month trial, if there has been improvement, then a pneumatic compression device is no longer considered reasonable and necessary.
- Pneumatic compression devices and appliances, segmental home model with calibrated gradient pressure, are experimental for CVI.
|
J9299 |
Basic benefit and medical policy
Code *J9299 *J9299 is now payable for the additional diagnosis of Z5111 and Z5112.
|
| POLICY CLARIFICATIONS |
0402T |
Basic benefit and medical policy
Corneal Collagen Cross-Linking policy
The criteria have been updated for the Corneal Collagen Cross-Linking policy, which is effective Nov. 1, 2019.
Inclusions:
Corneal collagen cross-linking using riboflavin and ultraviolet A may be considered medically necessary when one of the following conditions have been met:
- Keratoconus when the diagnosis has been established and progression of the disease is considered likely
- Corneal ectasia after refractive surgery
Exclusions:
Corneal collagen cross-linking using riboflavin and ultraviolet A is considered experimental for all other indications. |
20999
20939 |
Basic benefit and medical policy
Orthopedic applications of stem-cell therapy Procedure code *20939 has been added to the Orthopedic Applications of Stem-Cell Therapy (including Allografts and Bone Substituted used with Autologous Bone Marrow) policy.
Medical policy statement
Mesenchymal stem cell therapy is considered experimental for all orthopedic applications, including use in repair or regeneration of musculoskeletal tissue.
Allograft bone products containing viable stem cells, including, but not limited to, demineralized bone matrix with stem cells, are considered experimental for all orthopedic applications.
Allograft or synthetic bone graft substitutes that must be combined with autologous blood or bone marrow are considered experimental for all orthopedic applications.
The safety and efficacy of these treatments haven’t been established.
The policy effective date is Nov. 1, 2019. |
Established
33418, 33419, 0345T
Investigational
0543T, 0544T |
Basic benefit and medical policy
Measurement transcatheter mitral valve repair Procedure codes *0543T and *0544T have been added to the Transcatheter Mitral Valve Repair policy as experimental. This policy is effective Nov. 1, 2019.
Medical policy statement
The safety and effectiveness of transcatheter mitral valve repair have been established and may be considered a useful option when performed with an FDA-approved transcatheter valve device and specified criteria are met.
The safety and efficacy of transcatheter implantable mitral valve annulus reshaping devices for the treatment of mitral valve regurgitation are under clinical trial evaluation. Therefore, this service is experimental.
Inclusions:
Transcatheter mitral valve repair with an FDA-approved mitral valve repair system (i.e., Mitraclip®) is indicated when all the following criteria are met:
- Significant symptomatic mitral regurgitation (MR ≥ 3+) due to one of the following:
- Primary abnormality of the mitral apparatus (degenerative MR)
- Heart failure and secondary mitral regurgitation despite the use of maximally tolerated guideline-directed medical therapy
- Patients who have been determined to be at prohibitive risk for open mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease
- Existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
Exclusions:
- Patients who can’t tolerate procedural anticoagulation or post procedural antiplatelet regimen
- Active endocarditis of the mitral valve
- Rheumatic mitral valve disease
- Evidence of intracardiac, inferior vena cava or femoral venous thrombus
- The individual is an appropriate candidate for the standard, open surgical approach but has refused
- Transcatheter mitral valve annulus reshaping devices are under clinical trials
- Non-FDA approved systems or approaches including:
- Permavalve™ system
- Transseptal and transapical approach
|
83987, 95012 |
Basic benefit and medical policy
Exhaled nitric oxide and exhaled breath condensate Measurement of exhaled nitric oxide in the diagnosis and management of asthma, eosinophilic asthma and other respiratory disorders, including but not limited to, chronic obstructive pulmonary disease and chronic cough is considered experimental.
Measurement of exhaled breath condensate in the diagnosis and management of asthma and other respiratory disorders, including but not limited to, chronic obstructive pulmonary disease and chronic cough is considered experimental.
The clinical utility of exhaled nitric oxide and exhaled breath condensate in the diagnosis and management of pulmonary disease hasn’t been demonstrated. In addition, there is insufficient evidence that the use of these tests improves health outcomes.
This policy update is effective Nov. 1, 2019. |
81345 |
Basic benefit and medical policy
Molecular markers in FNA of thyroid In September, we published updated policy guidelines regarding molecular markers in fine needles aspirates of the thyroid. CPT code *81345 should have been included to report telomerase reverse transcriptase, or TERT, testing, a noncovered procedure.
|
95249, 95250, 95251, A9276, A9277, A9278, A9279, K0553, K0554
Not covered:
0446T, 0447T, 0448T, 99091, S1030, S1031 |
Basic benefit and medical policy
Continuous glucose monitoring systems The safety and effectiveness of FDA-approved continuous glucose monitoring systems, on an intermittent (72 hours or greater) or continuous basis, have been established. Both may be considered useful therapeutic devices for patients meeting the relevant patient selection criteria.
Implantable continuous glucose monitoring systems (e.g., Eversense® Continuous Glucose Monitoring System) is considered experimental.
Policy updates are effective Nov. 1, 2019.
Inclusions:
Seventy-two-hour monitoring of glucose levels in interstitial fluid, to optimize patient management, may be considered established in the following situations when any of the following criteria are met:
- Patients with insulin requiring diabetes who, despite current use of best practices, have poorly controlled diabetes, including hemoglobin A1c not in acceptable target range for the patient’s clinical situation, unexplained hypoglycemic episodes, evidence suggesting postprandial hyperglycemia or recurrent diabetic ketoacidosis.
- Patients with insulin requiring diabetes before insulin pump initiation to determine basal insulin levels.
- Women with insulin-requiring diabetes who are pregnant or about to become pregnant and have poorly controlled diabetes.
Continuous (i.e., long-term) monitoring of glucose levels in interstitial fluid, including real-time monitoring, as a technique in diabetic monitoring may be considered established in any of the following situations:
- Patients with insulin requiring diabetes who have demonstrated an understanding of the technology, are motivated to use the device correctly and consistently, are expected to adhere to a comprehensive diabetes treatment plan supervised by a qualified provider, and are capable of using the device to recognize alerts and alarms
- Patients with insulin-requiring diabetes who have recurrent, unexplained, severe (generally blood glucose levels <50 mg/dL) hypoglycemia or impaired awareness of hypoglycemia that puts the patient or others at risk
- Patients with poorly controlled insulin-requiring diabetes who are pregnant. Poorly controlled insulin-requiring diabetes includes unexplained hypoglycemic episodes, hypoglycemic unawareness, suspected postprandial hyperglycemia, and recurrent diabetic ketoacidosis.
- Patients who meet the criterion of recurrent unexplained severe hypoglycemia whose hypoglycemia puts the patient or others at risk and don’t already have an adequately functioning insulin pump may be considered for glucose sensors and transmitters associated with an integrated insulin pump.
Note: Patients need to meet criteria for continuous subcutaneous insulin infusion pumps and the criteria for the CGMS. Reference individual certificate or contract for specific coverage guidelines and limitations.
Replacement:
Replacement of a CGMS may be considered when:
- The transmitter is out of warranty or replacement parts are unavailable.
- The transmitter is malfunctioning and there is documented evidence of patient compliance provided, if no evidence of compliance is provided or if the member is not compliant, benefit of CGMS may be withdrawn.
Continuation of sensor use after one year may be considered when both of the following criteria are met:
- The CGMS has been previously approved by the health plan or the CGMS is in use before the user enrolling in the health plan.
- There is documented evidence of patient compliance provided, if no evidence of compliance is provided or if the member isn’t compliant, benefit of CGMS may be withdrawn.
All covered supplies must be compatible with the CGMS.
Exclusions:
Other uses of continuous monitoring of glucose levels in interstitial fluid (including real-time monitoring) as a technique of diabetic monitoring are considered experimental, including:
- Patients not meeting the inclusionary criteria above
- For convenience purposes, such as, but not limited to, lifestyle or employment circumstances
|
Established
99183
G0277
Investigational
A4575
E0446 |
Basic benefit and medical policy
Hyperbaric Oxygen Therapy, Systemic and Topical The inclusion criteria have been updated for the Hyperbaric Oxygen Therapy, Systemic and Topical medical policy. This policy is effective Nov. 1, 2019.
Inclusions:
The following conditions are effectively treated by systemic hyperbaric oxygen therapy (this list may not be all-inclusive):
- Acute peripheral arterial insufficiency
- Acute traumatic peripheral ischemia: HBOT is a valuable adjunctive treatment to be used in combination with accepted standard therapeutic measures when loss of function, limb or life is threatened
- Carbon monoxide poisoning/intoxication, acute
- Chronic refractory osteomyelitis, unresponsive to conventional medical and surgical management
- Crush injuries and suturing of severed limbs as an adjunctive treatment when loss of function, limb or life is threatened
- Cyanide poisoning, acute
- Decompression illness
- Diabetic wounds of the lower extremities in patients who meet all the following criteria:
- A diagnosis of Type 1 or Type 2 diabetes with a lower extremity wound that is due to diabetes
- A wound classified as Wagner Grade 3 or higher
The Wagner classification system of wounds is defined as follows:
Grade 0: No open lesion
Grade 1: Superficial ulcer without penetration to deeper layers
Grade 2: Ulcer penetrates to tendon, bone or joint
Grade 3: Lesion has penetrated deeper than Grade 2 and there is abscess, osteomyelitis, pyarthrosis, plantar space abscess or infection of the tendon and tendon sheaths
Grade 4: Wet or dry gangrene in the toes or forefoot
Grade 5: Gangrene involves the whole foot or such a percentage that no local procedures are possible and amputation (at least at the below the knee level) is indicated
- The patient has failed an adequate course of standard wound therapy. Standard wound care in patients with diabetic wounds includes all the following:
- The assessment of a patient’s vascular status and correction of any vascular problems in the affected limb if possible
- The optimization of nutritional status
- Optimization of glucose control
- Debridement by any means to remove devitalized tissue
- Maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings
- Appropriate off-loading
- Necessary treatment to resolve any infection that might be present
- Gas embolism, acute
- Gas gangrene (i.e., clostridial myonecrosis)
- Non-diabetic wounds:
- There is no measurable sign of healing for at least 30 consecutive days or when there is failure to respond to standard wound care.
- Wounds must be evaluated at least every 30 days during administration of HBOT for measurable signs of improvement. (See exclusion criteria.)
- Osteoradionecrosis as an adjunct to conventional treatment
- Pre- and post-treatment for patients undergoing dental surgery (non-implant related) of an irradiated jaw
- Preparation and preservation of compromised skin grafts (not for primary management of wounds)
- Profound anemia with exceptional blood loss: only when blood transfusion is impossible or must be delayed
- Progressive necrotizing infections
- Refractory mycoses: mucormycosis, actinomycosis, Conidiobolus coronata only as an adjunct to conventional therapy when the disease process is refractory to antibiotics and surgical treatment**
- Soft-tissue radiation necrosis (e.g., radiation enteritis, cystitis, proctitis) as an adjunct to conventional treatment
Wounds, including diabetic wounds, being treated with hyperbaric oxygen therapy, must be reviewed using clinical documentation that identifies measurable signs of healing, e.g. width, depth and length of the wound.
**For several of the indications included, there is little published evidence to support the effectiveness of hyperbaric oxygen therapy. However, there is little likelihood of RCTs being done for such relatively rare indications. Generally, these patients present with clinically severe situations where therapeutic options are limited. Subject matter expert experience and limited available evidence support that hyperbaric oxygen treatment may offer therapeutic benefit in these cases.
Exclusions:
- Topical hyperbaric oxygen therapy
- Hyperbaric oxygen pressurization is considered investigational in the treatment of the following conditions, (this list may not be all-inclusive):
- Acute coronary syndromes and as an adjunct to coronary interventions, including but not limited to percutaneous coronary interventions and cardiopulmonary bypass
- Acute or chronic cerebral vascular insufficiency
- Acute ischemic stroke
- Acute osteomyelitis, refractory to standard medical management
- Acute thermal and chemical pulmonary damage, i.e., smoke inhalation with pulmonary insufficiency
- Acute surgical and traumatic wounds
- Arthritic diseases
- Autism spectrum disorders
- Bell palsy
- Bisphosphonate-related osteonecrosis of the jaw
- Bone grafts
- Brown recluse spider bites
- Carbon tetrachloride poisoning, acute
- Cardiogenic shock
- Cerebral edema; acute
- Cerebral palsy
- Cerebrovascular disease, acute (thrombotic or embolic) or chronic
- Chronic arm lymphedema following radiotherapy for cancer
- Chronic peripheral vascular insufficiency
- Chronic wounds, other than those situations under the inclusions
- Cosmetic use
- Delayed onset muscle soreness
- Demyelinating diseases, e.g., multiple sclerosis, amyotrophic lateral sclerosis
- Fibromyalgia
- Fracture healing
- Hepatic necrosis
- Herpes zoster
- Hydrogen sulfide poisoning
- Idiopathic femoral neck necrosis
- Idiopathic sudden sensorineural hearing loss
- Inflammatory bowel disease (Crohn disease or ulcerative colitis)
- Intra-abdominal and intracranial abscesses
- In vitro fertilization
- Lepromatous leprosy
- Meningitis
- Mental illness (i.e., posttraumatic stress disorder, generalized anxiety disorder or depression)
- Migraine
- Motor dysfunction associated with stroke
- Multiple sclerosis
- Myocardial infarction
- Non-diabetic wounds:
- Continued treatment should be discontinued when there are no measurable signs of healing within any 30-day period of treatment. (See inclusions.)
- Nonvascular causes of chronic brain syndrome (Pick’s disease, Alzheimer’s disease, Korsakoff’s disease)
- Organ storage
- Organ transplantation
- Pseudomembranous colitis (antimicrobial agent-induced colitis)
- Pulmonary emphysema
- Pyoderma gangrenosum
- Radiation-induced injury in the head and neck, except as noted under the inclusions
- Retinal artery insufficiency, acute
- Retinopathy, adjunct to scleral buckling procedures in patients with sickle cell peripheral retinopathy and retinal detachment
- Senility
- Septicemia, aerobic
- Septicemia (anaerobic) and infection other than clostridial
- Severe or refractory Crohn’s disease
- Sickle cell crisis and/or hematuria
- Skin burns (thermal), acute
- Spinal cord injury
- Tetanus
- Traumatic brain injury
- Tumor sensitization for cancer treatments, including but not limited to, radiotherapy or chemotherapy
- Vascular dementia
|
E0650, E0651, E0652, E0655, E0656, E0657, E0660, E0665, E0666, E0667, E0668, E0669, E0671, E0672, and E0673
Investigational: E0676, E1399 |
Basic benefit and medical policy
Pneumatic compression pumps and appliances for lymphedema The medical policy statement has been updated for Pneumatic Compression Pumps and Appliances (e.g., Flexitouch™ System) for Lymphedema.
Medical policy statement
Pneumatic compression pumps and appliances for upper and lower extremities are established for the treatment of lymphedema in individuals who have failed conservative therapies.
Pneumatic compression pumps and appliances for the trunk or chest are established. It may be considered a useful therapeutic option when indicated.
Pneumatic compression pumps and appliances for the head or neck are experimental. This service hasn’t been scientifically demonstrated to improve patient clinical outcomes.
Inclusions:
Single-compartment or multichamber nonprogrammable (without calibrated gradient pressure) lymphedema pumps applied to the limb is established for the treatment of lymphedema that has failed to respond to conservative measures, such as elevation of the limb and use of compression garments.
Single-compartment or multichamber programmable (with calibrated gradient pressure) lymphedema pumps applied to the limb are established for the treatment of lymphedema when all of the following are met:
- When the individual is otherwise eligible for nonprogrammable pumps.
- When there is documentation that the individual has unique characteristics that prevent satisfactory pneumatic compression with single-compartment or multichamber nonprogrammable lymphedema pumps (e.g., significant scarring).
The use of lymphedema pumps and appliances to treat the trunk or chest is limited to individuals with all of the following:
- Lymphedema beyond the upper and lower extremities
- Have failed conservative therapy
- Have failed therapy with lymphedema pumps and appliances to the upper and lower extremities only
Exclusions:
Single-compartment or multichamber lymphedema pumps applied to the limb are considered investigational in all situations not mentioned above.
The use of lymphedema pumps to treat head or neck lymphedema in patients is considered experimental.
This policy is effective Nov. 1, 2019. |
J0178 |
Basic benefit and medical policy
Diabetic retinopathy for Eylea Effective May 13, 2019, the indication for diabetic retinopathy for Eylea (aflibercept) no longer requires the patient to also have diabetic macular edema. This is in alignment with the updated FDA-approved indications.
Eylea (aflibercept) is a vascular endothelial growth factor, or VEGF, inhibitor indicated for the treatment of patients with:
- Neovascular (wet) age-related macular degeneration, or AMD
- Macular edema following retinal vein occlusion, or RVO
- Diabetic macular edema
- Diabetic retinopathy
Dosage information:
Neovascular (wet) age-related macular degeneration
- The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection every four weeks (approximately every 28 days, monthly) for the first three months, followed by 2 mg (0.05 mL) via intravitreal injection once every eight weeks (two months).
- Although Eylea may be dosed as frequently as 2 mg every four weeks (approximately every 25 days, monthly), additional efficacy wasn’t demonstrated in most patients when Eylea was dosed every four weeks compared to every eight weeks. Some patients may need four-week (monthly) dosing after the first 12 weeks (three months).
- Although not as effective as the recommended every eight-week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.
Macular edema following retinal vein occlusion
- The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection once every four weeks (approximately every 25 days, monthly).
Diabetic macular edema and diabetic retinopathy
- The recommended dose for Eylea is 2 mg (0.05 mL) administered by intravitreal injection every four weeks (approximately every 28 days, monthly) for the first five injections followed by 2 mg (0.05 mL) via intravitreal injection once every eight weeks (two months).
- Although Eylea may be dosed as frequently as 2 mg every four weeks (approximately every 25 days, monthly), additional efficacy wasn’t demonstrated in most patients when Eylea was dosed every four weeks compared to every eight weeks. Some patients may need every four-week (monthly) dosing after the first 20 weeks (five months).
Pharmacy doesn’t require prior authorization of this drug.
NDC: 61755-0005-02 |
L6026, L6715, L6880, L6881, L6882, L6920, L6925, L6930, L6935, L6940, L6945, L6950, L6955, L6965, L6975, L7007, L7008, L7009, L7045, L7170, L7180, L7181, L7185, L7186, L7190, L7191, L7259
Other codes investigational: L8701, L8702 |
Basic benefit and medical policy
Myoelectric prosthetic and orthotic components for the upper limb The criteria for the Myoelectric Prosthetic and Orthotic Components for the Upper Limb policy have been updated. This policy is effective Nov. 1, 2019.
Medical policy statement
The safety and effectiveness of myoelectronic prostheses have been established. They may be considered useful therapeutic options for carefully selected candidates.
The safety and effectiveness of myoelectronic prosthesis with whole hand individually powered digits have been established. They may be considered useful therapeutic options for carefully selected candidates.
A partial hand prosthesis with individually powered digits is considered experimental.
Myoelectric controlled upper-limb orthoses (e.g., MyoPro) are considered experimental.
Inclusionary and exclusionary guidelines (clinically based guidelines that may support individual consideration and pre-authorization decisions)
Myoelectric upper-limb prosthetic components may be considered established when all the following conditions are met:
- The patient has an amputation or missing limb at the wrist or above (forearm, elbow, etc.).
- Standard body-powered prosthetic devices can’t be used or are insufficient to meet the functional needs of the individual in performing activities of daily living.
- The remaining musculature of the arm contains the minimum microvolt threshold to allow operation of a myoelectric prosthetic device.
- The patient has demonstrated sufficient neurologic and cognitive function to operate the prosthesis effectively.
- The patient is free of comorbidities that could interfere with function of the prosthesis (neuromuscular disease, etc.).
- Functional evaluation indicates that with training, use of a myoelectric prosthesis is likely to meet the functional needs of the individual (e.g., gripping, releasing, holding, coordinating movement of the prosthesis) when performing activities of daily living. This evaluation should consider the patient’s needs for control, durability (maintenance), function (speed, work capability) and usability.
Myoelectric upper-limb prosthetic components may be considered established in children age 2 years or older who have shown at least six months successful use of a passive prosthetic device and have a minimum EMG signal of 6μV threshold.
Myoelectric upper-limb whole prosthetic hands with independent articulating digits (L6880) may be considered established when all the following conditions are met:
- Must meet the above criteria for a myoelectric upper limb prosthetic.
- The patient has an amputation or missing limb at the wrist or above (forearm, elbow, etc.).
- A standard myoelectric prosthesis has been used for one year or more and found insufficient to meet the functional needs of the individual in performing activities of daily living.
Exclusions:
- Patients with a partial hand prosthesis with independent articulating digits
- Patients whose ADLs require frequent lifting of heavy objects (12 pounds or greater)
- Patients whose environments involve frequent contact with dirt, dust, grease, water and solvent
- Patients whose neuromas or phantom limb pain are exacerbated with the use of the prosthesis
- Myoelectric controlled upper-limb orthoses for individuals with upper-extremity weakness or paresis
Myoelectric upper-limb prosthetic components are considered not established under all other conditions. |
| GROUP BENEFIT CHANGES |
Orchid Orthopedic Solutions |
Orchid Orthopedic Solutions, group number 71793, is joining Blue Cross Blue Shield of Michigan, effective Jan. 1, 2020.
Group number: 71793
Alpha prefix: PPO (MYT)
Platform: NASCO hybrid
Plans offered:
PPO, medical/surgical
Vision
Prescription drugs
|
|
